RT Journal Article
SR Electronic
T1 Bridging the polar and hydrophobic metabolome in single-run untargeted liquid chromatography-mass spectrometry dried blood spot metabolomics for clinical purposes
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.03.22.21254119
DO 10.1101/2021.03.22.21254119
A1 Skogvold, Hanne Bendiksen
A1 Mørk Sandås, Elise
A1 Østeby, Anja
A1 Løkken, Camilla
A1 Rootwelt, Helge
A1 Rønning, Per Ola
A1 Wilson, Steven Ray
A1 Prestø Elgstøen, Katja Benedikte
YR 2021
UL http://medrxiv.org/content/early/2021/03/26/2021.03.22.21254119.abstract
AB Dried blood spot (DBS) metabolite analysis is a central tool for the clinic, e.g. newborn screening. Instead of applying multiple analytical methods, a single liquid chromatography-mass spectrometry (LC-MS) method was developed for metabolites spanning from highly polar glucose to hydrophobic long-chain acylcarnitines. For liquid chromatography, a diphenyl column and a multi-linear solvent gradient operated at elevated flow rates allowed for an even-spread resolution of diverse metabolites. Injecting moderate volumes of DBS organic extracts directly, in contrast to evaporation and reconstitution, provided substantial increases in analyte recovery. Q Exactive MS settings were also tailored for sensitivity increases, and the method allowed for analyte retention time and peak area repeatabilities of 0.1-0.4 % and 2-10 %, respectively, for a wide polarity range of metabolites (logP −4.4 to 8.8). The method’s performance was suited for both untargeted analysis as well as targeted approaches, evaluated in clinically relevant experiments.Competing Interest StatementThe authors have declared no competing interest.Funding StatementInternal funding: Financial support from UiO:Life Science (University of Oslo) is gratefully acknowledged. External funding: This work was also partially supported by the Research Council of Norway through its Centre of Excellence scheme, project number 262613. S.R.W. is a member of the National Network of Advanced Proteomics Infrastructure (NAPI), which is funded by the Research Council of Norway INFRASTRUKTUR-program (project number: 295910).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Approval by Regional Committees for Medical and Health Research Ethics: The use of whole blood from healthy volunteers was approved by the Regional Committees for Medical and Health Research Ethics (case number: 173346). Page to the organization: https://www.med.uio.no/english/about/organization/adm/rec-south-east/ All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data presented and described in this manuscript is from liquid chromatography-mass spectrometry recordings. The raw data files are available upon request.